Emerging Evidence for Neuropsycho-Consequences of COVID-19

Jingwen Li1,2, Xi Long1,2, Qing Zhang3, Xi Fang1, Fang Fang4, Xuefei Lv4, Dandan Zhang4, Yu Sun4, Na Li3, Shaoping Hu4,5, Zhicheng Lin5; and Nian Xiong1,3,6,*

1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; 2Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; 3Wuhan Red Cross Hospital, Wuhan, Hubei, China; 4Department of Radiology, Wuhan Red Cross Hospital, Wuhan, Hubei, China; 5Laboratory of Psychiatric Neurogenomics, McLean Hospital; Harvard Medical School; Belmont, MA 02478, USA

Abstract: The pandemic novel coronavirus disease (COVID-19) has become a global concern in which the respiratory system is not the only one involved. Previous researches have presented the common clinical manifestations including respiratory symptoms (i.e., fever and cough), fatigue and myalgia. However, there is limited evidence for neurological and psychological influences of SARS-CoV-2. In this review, we discuss the common neurological manifestations of COVID-19 including acute cerebrovascular disease (i.e., cerebral hemorrhage) and muscle ache. Possible viral transmission to the nervous system may occur via circulation, an upper nasal transcribrial route and/or conjunctival route. Moreover, we cannot ignore the psychological influence on the public, medical staff and confirmed patients. Dealing with public psychological barriers and performing psychological crisis intervention are an important part of public health interventions.

Keywords: Brain, indirect influence, neurological, SARS-COV-2, psychological, mental health, COVID-19, transmission.

1. INTRODUCTION

Severity and prognosis of the 2019 novel coronavirus disease (COVID-19), also known as novel coronavirus pneumonia (NCP), have become global concerns in terms of how to treat the patients because this novel disease affects many organs beyond lung [1, 2].

COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 named by WHO), which resembles and differs from SARS-CoV. One of the similarities is both viruses exploit the angiotensin converting enzyme 2 (ACE2) receptor to gain entry inside cells [3]. One main difference is that the former affects the lung as NCP in every patient but the later, not in every patient developing atypical pneumonia. The most characteristic symptom of NCP is respiratory distress, with a typical chest computer tomography (CT) finding of ground-glass opacity, similar to that of SARS [4]. Previous researches have presented the common clinical manifestations including respiratory symptoms (i.e., fever and cough), fatigue and myalgia. However, other less common symptoms indicated the influence on other organs and systems. Recent retrospective case series study of Dr. Mao and colleagues [5] discussed neurological manifestations of hospitalized patients with COVID-19. Dr. Li et al reasoned that the respiratory failure may partly be due to a neuroinvasive potential of SARS-CoV-2 [6].

If the NCP onset seemed mainly about nervous system diseases, it could be easily misdiagnosed. And these patients might become invisible sources of transmission. Therefore, it is important to understand the neurological symptoms and possible underlying mechanisms in patients with SARS-CoV-2. In addition, it has been reported that there is a panic among both the sick and the healthy about this new pandemic [7, 8]. Besides the conventional treatment of COVID-19, we should pay attention to the patients’ brain health at the same time.

2. COMMON NEUROLOGICAL MANIFESTATIONS

Neurological symptoms can be categorized into three main areas: central nervous system (CNS) symptoms or disease, peripheral nervous system (PNS) symptoms and muscular symptoms. In patients with CNS symptoms, the most common complaints were dizziness and headache. In patients with PNS symptoms, the most common complaints were hypoguesia and hyposmia [5]. Muscle injury was defined when a patient had myalgia and elevated serum creatine kinase (CK) level above 200 U/L. The common neu-
r pathological manifestations of COVID-19 patients are summarized in Table 1 [9].

Some patients with conscious disturbance require a head CT examination to exclude acute cerebrovascular disease (i.e., ischemic stroke and cerebral hemorrhage). Older severe patients with elevated D-dimer [9], which is indicative of the consumptive coagulation system, are more likely to have vascular thrombosis, leading to ischemic stroke. SARS-CoV-2 can bind to the ACE2 receptor so the blood pressure of some hypertension patients may elevate abnormally, increasing the risk for cerebral hemorrhage [10, 11]. In NCP patients, symptoms of headache, epilepsy and impaired consciousness could be also investigated [12]. Additionally, symptoms of sore limbs and muscle weakness can be seen in COVID-19 patients. High levels of CK in these patients indicate muscle damage caused by SARS-CoV-2.

### 3. TRANSMISSION MECHANISMS OF NERVOUS SYSTEMS

Viremia et al discussed the dissemination of the COVID-19 virus SARS-CoV-2 throughout the body via the bloodstream. The neuroinvasive propensity has been demonstrated as a common feature of coronavirus so that neurotropism may occur via circulation, an upper nasal trancribrial route and/or conjunctival route [25-27].

The presence of SARS-CoV-2 in the circulation understandably enables it passing into the cerebral circulation. Patients with SARS have also demonstrated the presence of SARS-CoV in their cerebrospinal fluid, and autopsy findings of such patients have become strong evidence for the viral presence in the brain. The viruses were localized almost exclusively in the neurons, confirming that these viruses can cross the blood-brain barrier and enter the CNS. Once within the milieu of the neuronal tissues, its interaction with ACE2 receptors expressed on the plasma membrane of neurons can initiate a cycle of viral budding accompanied by neuronal damage without substantial inflammation as has been seen with cases of SARS-CoV in the past [25]. ACE2 receptors are targets of SARS-CoV-2 as well [28, 29]. SARS-CoV-2 uses its spike protein S1 that enables the attachment of the virion to the cell membrane by interacting with the host ACE2. The latest study showed that the ACE2 binding affinity for the SARS-CoV-2 spike protein ectodomain was 10 - 20-fold higher than that of the SARS-CoV [30], partly explaining why COVID-19 has been so highly contagious. Of the note, the brain expresses ACE2 receptors, on glial cells and neurons [25]. The expression of ACE2 in the brain is shown in Fig. 1.

Previous studies in transgenic mice revealed that either SARS-CoV [27] or MERS-CoV [31], when given intranasally, could enter the brain, possibly via the olfactory nerves, and thereafter rapidly spread to some specific brain areas such as the brainstem [32]. The spread of SARS-CoV-2 to the brain has been supported by a case with hypoxia and cases with acute respiratory failure in COVID-19 [6]. Additionally, SARS-CoV-2 transmission through the ocular surface was reported. Infectious droplets and body fluids can easily contaminate the human conjunctival epithelium [26].

### 4. PSYCHOLOGICAL INFLUENCE

Numerous patients have been infected with SARS-CoV-2 since the outbreak of COVID-19 in Wuhan, China. For health-care sectors, dealing with public psychological barriers and performing psychological crisis intervention are an important part of public health interventions. Besides the
public, confirmed patients and frontline medical staff were affected to various degrees. The National Health Commission of China has released guidelines for local authorities to promote psychological crisis intervention in related patients, medical personnel, and others under medical observation [33].

4.1. The Public

In order to swiftly contain the spread of SARS-CoV-2, the Chinese government took a firm measure of the entire country quarantined, which has been extreme, astounding and unprecedented [34]. The epidemic brought to people in China and the world not only the risk of death due to the viral infection, but also unbearable psychological pressure which could not be ignored. Quarantine against COVID-19 on the one hand increases the possibility of psychological and mental problems. With interpersonal communication restricted under the introduction of quarantine, depression and anxiety are more likely to occur and worsen. On the other hand, quarantine reduces the availability of timely psychological intervention, and routine psychological counseling is also difficult to carry out in the current situation [35]. As reported on February 14th, 2020, a male patient with common cold committed suicide in India because he suspected he had COVID-19 and was fearing of infecting his family members [36]. A recent survey of the public in China was conducted to understand their levels of psychological impact, anxiety, depression, and stress during the initial stage of the COVID-19 outbreak. The results of the survey indicated that more than a half of the respondents rated themselves with psychological impact as moderate-to-severe and about one-third reported moderate-to-severe anxiety [37].

4.2. Medical Staff

To reduce the medical burden following the outbreak, a large number of medical staff were sent from other provinces to Wuhan city and Hubei province. These healthcare workers are caring for the either severely ill, scared, or lost of beloved but themselves also exposed to the trauma. The challenges and stress they experience could also induce common mental disorders, including anxiety and depressive disorders, and posttraumatic stress disorder [33]. It has been pointed out that a unique feature of some mental health doctors’ work is that through their role as therapists, they are exposed to the description and response of clients to trauma, which may indirectly cause pain and trauma to therapists. This is the proposed phenomenon known as "alternative trauma" or “vicarious traumatization (VT)” [38]. A previous study of VT during COVID-19 control examined frontline nurses engaged in the process of providing care for patients. The results showed that the VT scores for frontline nurses including scores for physiological and psychological responses were significantly worse than those of non-frontline nurses.
[39]. However, the VT scores for the general public were significantly higher than those of frontline nurses [39]. This study confirmed the psychological influence of COVID-19.

4.3. Confirmed Patients

During disease progression, clinical symptoms become severe and psychological problems in infected patients evolve at the same time [40]. Studies have confirmed that individuals who have experienced public health emergencies still have varying degrees of stress disorders, even after the event is over, or they have been cured and discharged from a hospital [41]. In this way, frontline healthcare workers again become the main personnel providing psychological interventions to patients in hospitals [40].

5. WHAT NEUROLOGISTS NEED TO KNOW

Neurologists should pay more attention to COVID-19 patients with abnormal blood clotting function as a high risk factor of stroke. Head CT and/or MRI should be performed to exclude the symptoms of acute cerebrovascular events and intracranial infection. With symptoms of muscle damage, nutritional support therapy is essential and gamma globulin intracranial infection. With symptoms of muscle damage, nutritional support therapy is essential and gamma globulin

CONCLUSION

For patients with COVID-19, especially those with great severity, there is an urgent need to understand the neurologic manifestations and neurotropic potential of COVID-19 in order to prioritize and individualize the treatment protocols based on particular cases and predominant organ involvement. Neurologists should consider SARS-CoV-2 infection as a differential diagnosis of patients with these neurologic manifestations, to avoid delayed diagnosis or misdiagnosis and ensure prevention of viral transmission. Moreover, psychological intervention measures should be introduced and adapted as appropriate.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was supported by grants 2016YFC1306600 and 2018YFC1314700 from the National Key R&D Program of China, grants 81873782 from the National Natural Science Foundation of China, grant 2016CBF624 from the National Science Foundation of Hubei Province, grant 2017J050304010278 from The Youth Science and Technology Morning Light Program of Wuhan City, 2018 Huabei medical research project WJ2019F030, 2018 Wuhan medical research project S201802140011, 2018 Wuhan Young and Middle-aged Medical Talents Program and 2017 Huabei Provincial Party Committee Organization Department the second batch of Huabei youth elite development plan (all to NX).

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Yao, X.H.; Li, T.Y.; He, Z.C.; Ping, Y.F.; Liu, H.W.; Yu, S.C.; Mou, H.M.; Wang, L.H.; Zhang, H.R.; Fu, W.J.; Luo, T.; Liu, F.; Chen, C.; Xiao, H.L.; Guo, H.T.; Lin, S.; Xiang, D.F.; Shi, Y.; Li, Q.R.; Huang, X.; Cui, Y.; Liu, X.Z.; Tang, W.; Pan, P.F.; Huang X.Q.; Ding, Y.Q.; Bian, X.W. A pathological report of three COVID-19 cases by minimally invasive autopsies Zonghua bing li jue za zhi = Chinese J. Pathology. 2020, 49(4), E5.
[2] Wang, T.; Du, Z.; Zhu, F.; Cao, Z.; An, Y.; Gao, Y.; Jiang, B. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet, 2020, 395(10228), e52. http://dx.doi.org/10.1016/S0140-6736(20)30558-4 PMID: 32171074
[3] Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; Müller, M.A.; Drosten, C.; Pöhlmann, S. SARS-CoV-2 cell entry depends on ace2 and transmem and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181(2), 271-280.e8. http://dx.doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651
[4] Xie, X.; Zhong, Z.; Zhao, W.; Zheng, C.; Wang, F.; Liu, J. Chest CT for typical 2019-nCoV pneumonia: Relationship to negative rt-PCR testing. Radiology, 2020, 296(2),E41-E45.
[5] Mao, L.; Jin, H.; Wang, M.; Hu, Y.; Chen, S.; He, Q.; Chang, J.; Hong, C.; Zhou, Y.; Wang, D.; Miao, X.; Li, Y.; Hu, B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. JAMA Neurol, 2020, 77(6), 683-690.
[6] Li, Y.C.; Bai, W.Z.; Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. J. Med. Virol., 2020, 92(6), 552-555. http://dx.doi.org/10.1002/jmv.25728 PMID: 32246783
[7] The Lancet. COVID-19: fighting panic with information (Editorial). Lancet, 2020, 395(10224), 537.
[8] http://dx.doi.org/10.1016/S0140-6736(20)30379-2 PMID: 32087777
[9] Depoux, A.; Martin, S.; Karafillisakis, E.; Preet, R.; Wilder-Smith, A.; Larson, H. The pandemic of social media panic travels faster than the COVID-19 outbreak. J. Travel Med., 2020, 27(3).
[10] Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; Du, B.; Li, L.J.; Zeng, G.; Yuen, K.Y.; Chen, R.C.; Tang, C.L.; Wang, T.; Chen, P.Y.; Xiang, M.; Li, S.Y.; Wang, J.L.; Liang, Z.J.; Peng, Y.X.; Wei, L.; Liu, Y.; Hu, Y.H.; Peng, P.; Wang, J.M.; Liu, J.Y.; Chen, Z.; Li, G.; Zheng, Z.J.; Qiu, S.Q.; Luo, J.; Ye, C.J.; Zhu, S.Y.; Zhong, N.S. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 2020, 382(18), 1708-1720. http://dx.doi.org/10.1056/NEJMoa2002032 PMID: 32109013
[11] Zhang, B.; Zhou, X.; Qiu, Y.; Song, Y.; Feng, F.; Feng, J.; Song, Q.; Jia, Q.; Wang, J. Clinical characteristics of 82 death cases with COVID-19. medRxiv preprint, 2020, 15(7), e2025458.
[12] Huang, Y.; Yang, R.; Xu, Y.; Gong, P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan. medRxiv preprint, 2020.
[13] Clinical strategies for prevention and treatment neurologist consensus editorial group, corona., 2019 clinical prevention and treatment of coronavirus disease (covid-19). Chin. J. Neurol., 2020, e001-e001.
[14] Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; Wu, Y.; Zhang, L.; Yu, Z.; Fang, M.; Yu, T.; Wang, Y.; Pan, S.; Zou, X.; Yuan, S.; Shang, Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med., 2020, 8(5), 475-481. http://dx.doi.org/10.1016/S2213-2600(20)30079-5 PMID: 32105632
[15] Xu, W.W.; Wu, X.X.; Jiang, X.G.; Xu, K.J.; Ying, L.J.; Ma, C.L.; Li, S.B.; Wang, H.Y.; Zhang, S.; Gao, H.N.; Sheng, J.P.; Cai, H.L.; Qiu, Y.Q.; Li, L.J. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ, 2020, 368, m606. http://dx.doi.org/10.1136/bmj.m606 PMID: 32075786

Emerging Evidence for Neuropsycho-Consequences of COVID-19

Current Neuropharmacology, 2021. Vol. 19, No. 1
Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhuan. JAMA. 2020, 323(11):1061-1066.

Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhuan. Lancet. 2020, 395(10223), 496-503.

Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L. Epidemiologic and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhuan, China: a descriptive study. Lancet. 2020, 395(10223), 507-513.

19 Virus targeting the CNS: Tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem. Neurosci., 2020, 11(7), 995-998.

20 Lu, C.W.; Liu, X.F.; Jia, Z.F. -nCoV transmission through the ocular surface must not be ignored. Lancet. 2019, 393(10124), e39. PMID: 3205510.

21 Chang, D.; Liu, M. G.; Wei, L.; Xie, L.X.; Zhu, G.F.; Cruz, C.S.; Sharm, L. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside wuhan. JAMA. 2020, 323(11), 1092-1093.

22 Wang, Z.; Chen, X.; Lu, Y.; Chen, F.; Zhang, W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. BioSci. Trends, 2020, 14(1), 64-68.

23 Liu, K.; Fang, Y.Y.; Deng, Y.; Liu, W.; Wang, M.F.; Ma, J.P.; Xiao, W.; Wang, Y.N.; Zhong, M.H.; Li, C.H.; Li, G.C.; Liu, H.G. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province. Chin. Med. J. (Engl.). 2020, 133(9), 1025-1031.

24 Chung, M.; Bernheim, A.; Mei, X.; Zhang, N.; Huang, M.; Zeng, X.; Cui, J.; Xu, W.; Yang, Y.; Faday, Z.A.; Jacob, A.; Li, K.; Li, S.; Shan, H. CT imaging features of 2019 novel Coronavirus (2019-nCoV). Radiology. 2020, 295(1), 202-207.

25 Pan, F.; Ye, T.; Sun, P.; Gui, S.; Liang, B.; Li, L.; Zheng, D.; Wang, J.; Hessketh, R.L.; Yang, L.; Zheng, C. Time course of lung changes on chest ct during recovery from 2019 novel coronavirus (COVID-19) Pneumonia. Radiology. 2020, 295(3), 715-721.

26 Song, F.; Shi, N.; Shan, F.; Zhang, Z.; Shen, J.; Lu, H.; Ling, Y.; Jiang, Y.; Shi, Y. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020, 295(1), 210-217.

27 Ren, L.L.; Wang, Y.M.; Wu, Z.Q.; Xiang, Z.C.; Guo, L.; Xu, T.; Jiang, Y.Z.; Xiong, Y.; Li, Y.J.; Li, X.W.; Li, H.; Fan, G.H.; Gu, X.Y.; Xiao, Y.; Gao, H.; Xu, J.Y.; Yang, F.; Wang, X.M.; Wu, C.; Chen, L.; Liu, Y.W.; Liu, B.; Yang, J.; Wang, X.R.; Dong, J.; Li, L.; Huang, C.L.; Zhao, J.P.; Hu, Y.; Cheng, Z.S.; Liu, L.L.; Gao, Z.H.; Qin, C.; Jin, Q.; Cao, B.; Wang, J.W. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin. Med. J. (Engl.). 2020, 133(9), 1015-1024.

28 Baig, A.M. Khaleeq; A; Ali, U; Syeda, H. Evidence of the COVID-19 Virus targeting the CNS: Tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem. Neurosci., 2020, 11(7), 995-998.

29 Lu, C.W.; Liu, X.F.; Jia, Z.F. -nCoV transmission through the ocular surface must not be ignored. Lancet. 2019, 393(10124), e39. PMID: 3205510

30 Netland, J.; Meyerholz, D.K.; Moore, S.; Cassell, M.; Perlman, S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol., 2008, 82(15), 7264-7275.

31 Li, K.; Wohlford-Lenane, C.; Perlman, S.; Zhao, J.; Jewell, A.K.; Reznikov, L.R.; Gibson-Corley, K.; Meyerholz, D.K.; McCray, P.B., Jr. Middle ear respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipetidyl peptidase 4. J. Infect. Dis., 2016, 213(5), 715-722.

32 Li, K.; Wohlford-Lenane, C.; Perlman, S.; Zhao, J.; Jewell, A.K.; Reznikov, L.R.; Gibson-Corley, K.; Meyerholz, D.K.; McCray, P.B., Jr. Middle ear respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipetidyl peptidase 4. J. Infect. Dis., 2016, 213(5), 715-722.